AI reads tumor slides to predict cancer return in early breast cancer

NCT ID NCT07541703

Ongoing Diagnosis Sponsor: Spotlight Medical Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing an artificial intelligence (AI) tool that analyzes digitized images of tumor tissue from 2,200 women with ER-positive, HER2-negative early breast cancer. The AI aims to predict the risk of cancer spreading to distant parts of the body. Researchers will compare the AI's predictions with actual patient outcomes to see how accurate it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence-based prognostic assay (diagnostic test)
What this could lead to: If successful, this AI tool could help doctors better predict which early breast cancer patients are at risk of distant recurrence, guiding treatment decisions.
What could go wrong: This is a retrospective observational study, not a prospective trial, so results may not apply to all patients. The AI tool's accuracy depends on the quality of stored tissue samples and data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER EARLY BREAST CANCER ER-POSITIVE HER2-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Medical University of Vienna, Center of Cancer Research

Vienna, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.